Published Date: 05 Apr 2023
Almost one in five adults in America has diabetes. The common condition is not, however, easy to manage or treat. The No. 1 cause of death worldwide is diabetes and its complications. One of the main causes of lower-limb and adult blindness.
Read Full NewsA randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.
A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
1.
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC
2.
Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma
3.
VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets
4.
New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada
5.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
1.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
2.
Comprehensive Standards in Oncology for Modern Medicine
3.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
4.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
5.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation